close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Medical History

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Medical History

Review your patient’s information.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Emese Zsiros

location-icon

Buffalo, NY

LOCATION OF PRACTICE
Roswell Park Comprehensive Cancer Center
MEDICAL Specialty:

Ovarian Cancer



NPI Number
1598921181
ABOUT

Emese Zsiros, MD, PhD, FACOG is an OB/GYN and gynecologic oncologist at Roswell Park Comprehensive Cancer Center. Dr. Zsiros serves as the Chair of the Department of Gynecologic Oncology, and she runs a translational lab where she and her team delve into cell therapies and the ovarian cancer tumor microenvironment, exploring strategies to mitigate immunosuppression and amplify the efficacy of immunotherapies.

Dr. Emese Zsiros profile image

Published Articles

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.- 2026 Apr 18
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.- 2026 Jan 9
BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer.- 2026 Jan 7
Reflections on Medical Trainee Unions and Health Care Systems.- 2025 Nov 4
Growing teratoma syndrome in a chemotherapy naïve patient.- 2025 Aug
NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.- 2025 Sep 1
Tertiary lymphoid structures: exploring opportunities to improve immunotherapy in ovarian cancer.- 2025
Mending the divide: integrating opioid analgesia and immunotherapy for optimal cancer care.- 2025 May 15
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors.- 2025 Mar 25
Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.- 2025 Feb

Clinical Trials

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors

My Patient Resources

Other Specialists treating Ovarian Cancer in Buffalo, NY

See All Doctors

Dr. Peter Frederick

Specialty: Ovarian Cancer, Peritoneal Cancer, Uterine Cancer

My Resources
location-icon

UPMC Chautauqua

My Resources

Dr. Stacey Akers

Specialty: Uterine Cancer, Ovarian Cancer, Destruction or Excision of Lesion of Cervix (incl. LEEP)

My Resources
location-icon

Sisters of Charity Hospital

My Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider